Log in

NASDAQ:CFMSConforMIS Stock Price, Forecast & News

$0.78
-0.03 (-3.70 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.75
Now: $0.78
$0.81
50-Day Range
$0.78
MA: $0.90
$1.04
52-Week Range
$0.50
Now: $0.78
$4.09
Volume1.14 million shs
Average Volume1.11 million shs
Market Capitalization$55.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Read More
ConforMIS logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.43 million
Book Value$0.24 per share

Profitability

Net Income$-28,480,000.00

Miscellaneous

Employees262
Market Cap$55.75 million
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

How has ConforMIS's stock been impacted by COVID-19 (Coronavirus)?

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CFMS shares have increased by 18.2% and is now trading at $0.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ConforMIS?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ConforMIS.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for ConforMIS.

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) released its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The medical instruments supplier earned $16.48 million during the quarter, compared to analysts' expectations of $18.95 million. ConforMIS had a negative return on equity of 165.61% and a negative net margin of 41.29%. View ConforMIS's earnings history.

What price target have analysts set for CFMS?

4 Wall Street analysts have issued 1-year price objectives for ConforMIS's shares. Their forecasts range from $2.00 to $3.00. On average, they expect ConforMIS's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 199.1% from the stock's current price. View analysts' price targets for ConforMIS.

Has ConforMIS been receiving favorable news coverage?

Media coverage about CFMS stock has trended negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ConforMIS earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future. View the latest news about ConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a decline in short interest in June. As of June 15th, there was short interest totaling 2,350,000 shares, a decline of 20.6% from the May 31st total of 2,960,000 shares. Based on an average daily volume of 574,700 shares, the short-interest ratio is presently 4.1 days. Approximately 3.7% of the company's shares are sold short. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Advanced Micro Devices (AMD), Alibaba Group (BABA), AbbVie (ABBV), Pfizer (PFE) and Starbucks (SBUX).

Who are ConforMIS's key executives?

ConforMIS's management team includes the following people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $0.78.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $55.75 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe.

What is ConforMIS's official website?

The official website for ConforMIS is www.conformis.com.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.